Genpharmasec Board of Directors
Get the latest insights into the leadership at Genpharmasec. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Ulhas Narayan Deosthale | Executive Director |
| Mrs. Sneha Sadhwani | Non Exe.Non Ind.Director |
| Mr. Rajesh Mirchumal Sadhwani | Non Exe.Non Ind.Director |
| Mr. Siddhesh Shende | Independent Director |
| Mr. Mayur Bhatt | Independent Director |
| Mr. Sachin Prakash Aphandkar | Independent Director |
Genpharmasec Share price
GENPHARMA
1.57
0.03 (-1.88%)Last updated on 4 Nov, 2025 | 15:54 IST
BUYSELL
Today's High
1.64
Today's Low
1.55
52 Week Low
1.55
52 Week High
4.32
The current prices are delayed, login to your account for live prices
LoginGenpharmasec FAQs
The board at Genpharmasec consists of experienced professionals, including Mr. Ulhas Narayan Deosthale , Mrs. Sneha Sadhwani , and others, overseeing the company’s strategic and corporate governance.
Directors at Genpharmasec are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Ulhas Narayan Deosthale is the current chairman at Genpharmasec.
Executive directors at Genpharmasec are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Genpharmasec adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Genpharmasec, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.